PET/CT in paediatric malignancies - An update.
(18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a well-established imaging modality in adult oncological practice. Its role in childhood malignancies needs to be discussed as paediatric malignancies differ from adults in tumor subtypes and they have different tumor biology and FDG uptake patterns. This is also compounded by smaller body mass, dosimetric restrictions, and physiological factors that can affect the FDG uptake. It calls for careful planning of the PET study, preparing the child, the parents, and expertise of nuclear physicians in reporting pediatric positron emission tomography/computed tomography (PET/CT) studies. In a broad perspective, FDG-PET/CT has been used in staging, assessment of therapy response, identifying metastases and as a follow-up tool in a wide variety of pediatric malignancies. This review outlines the role of PET/CT in childhood malignancies other than hematological malignancies such as lymphoma and leukemia.
Department of Nuclear Medicine and PET/CT, Amrita Institute of Medical Sciences, Cochin, Kerala, India.
Subramanyam
S
Padma
Department of Nuclear Medicine and PET/CT, Amrita Institute of Medical Sciences, Cochin, Kerala, India.
Palaniswamy Shanmuga
PS
Sundaram
Department of Nuclear Medicine and PET/CT, Amrita Institute of Medical Sciences, Cochin, Kerala, India.
Anshu
A
Tewari
Central nervous system tumors; childhood malignancies; neuroblastoma; positron emission tomography/computed tomography; sarcoma
J Clin Endocrinol Metab. 2007 Dec;92 (12 ):4706-11
17895314
Eur J Nucl Med Mol Imaging. 2009 Dec;36(12 ):1944-51
19593561
Anesthesiology. 2002 Apr;96(4):1004-17
11964611
J Nucl Med. 2007 Jan;48 Suppl 1:4S-18S
17204716
Radiology. 1996 Jun;199(3):743-50
8637999
J Clin Oncol. 1997 Feb;15(2):594-603
9053482
J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16
10655437
Blood. 1999 Jul 15;94(2):429-33
10397709
Horm Res. 2006;66(1):40-2
16710094
Semin Nucl Med. 2008 Jul;38(4):240-50
18514080
N Engl J Med. 1997 Jul 24;337(4):242-53
9227931
J Pediatr Hematol Oncol. 1997 Jul-Aug;19(4):334-8
9256833
Eur J Nucl Med Mol Imaging. 2002 Jan;29(1):61-6
11807608
Surg Oncol. 2007 Nov;16(3):195-203
17714939
J Neurol Neurosurg Psychiatry. 1995 Feb;58(2):250-2
7876865
Eur J Nucl Med. 2000 Sep;27(9):1305-11
11007511
Clin Nucl Med. 2000 Nov;25(11):874-81
11079583
J Nucl Med. 2006 May;47(5):885-95
16644760
J Nucl Med. 2001 Mar;42(3):432-45
11337520
Arch Neurol. 1999 Apr;56(4):421-5
10199329
J Nucl Med. 1993 Nov;34(11):1936-43
8229238
J Neurosurg. 1996 Jan;84(1):148-9
8613825
J Nucl Med. 1995 Apr;36(4):644-50
7699460
Pediatr Surg Int. 2005 May;21(5):341-5
15834579
AJR Am J Roentgenol. 2004 May;182(5):1214-6
15100121
Clin Orthop Relat Res. 2006 Sep;450:101-4
16906103
Oncologist. 2008 Jul;13(7):812-20
18644850
Int J Health Serv. 2007;37(3):419-39
17844927
Biochim Biophys Acta. 1986 Nov 19;884(2):276-81
3533158
Cancer J. 2004 Jul-Aug;10 (4):234-42
15383204
AJNR Am J Neuroradiol. 1998 Mar;19(3):407-13
9541290
Eur J Nucl Med Mol Imaging. 2003 Mar;30(3):344-53
12634961
J Nucl Med. 2002 Sep;43(9):1210-7
12215561
J Nucl Med. 1998 Jul;39(7):1302-5
9669415
Wien Klin Wochenschr. 2007;119(19-20):579-84
17985091
Eur J Nucl Med Mol Imaging. 2008 Jul;35(7):1323-9
18347794
Panminerva Med. 2006 Mar;48(1):33-40
16633330
Surg Oncol. 2008 Jul;17(1):33-40
17935976
J Nucl Med. 1998 Mar;39(3):490-4
9529297
J Clin Oncol. 2008 May 10;26(14):2379-83
18467729
J Nucl Med. 1996 Feb;37(2):387-93
8667081
PET Clin. 2014 Apr;9(2):195-208
25030282
J Nucl Med. 2005 Jun;46(6):945-52
15937304
Semin Nucl Med. 2007 Sep;37(5):316-31
17707239
J Nucl Med. 2006 Oct;47(10 ):1635-42
17015899
Radiology. 2002 Sep;224(3):748-56
12202709
Eur J Surg Oncol. 1995 Feb;21(1):78-82
7851559
Pediatrics. 1992 Jun;89(6 Pt 1):1110-5
1594358
Pediatr Blood Cancer. 2010 Feb;54(2):222-7
19890901
J Nucl Med Technol. 2003 Mar;31(1):3-7; quiz 8-10
12624120
J Neurooncol. 2003 Sep;64(3):227-37
14558598
J Nucl Med. 2004 Nov;45(11):1931-8
15534065
J Nucl Med. 2007 Sep;48(9):1468-81
17704239